Cyclophosphamide vs mycophenolate
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes onlyRD 0.03 [0, 0.06]2 studies · 300 participantsLow